Prilosec OTC Forced Name Change Rejected As FDA Clears Pending Petitions
This article was originally published in The Tan Sheet
Executive Summary
A lack of data supporting consumer confusion claims between nonprescription Prilosec and the eponymous Rx version is cited by FDA in a letter denying a citizen petition. The petitioner sought an agency-mandated name change
You may also be interested in...
Prilosec OTC Patent Extension Submission Pending At PTO
AstraZeneca appears to be building its case to ward off eventual private label competition for Prilosec OTC upon expiration of Hatch/Waxman exclusivity
Prilosec OTC Name Will Create Consumer Confusion With Rx Drugs – Petition
FDA should require that Prilosec OTC be sold under a different brand name to "reduce the risk of consumer confusion" resulting from extensive direct-to-consumer advertising for the Rx version of the drug, an Aug. 12 citizen petition says
Prilosec OTC Approved In 28-, 42-Count Multiple Regimen Sizes
FDA's June 20 approval of Procter & Gamble/ AstraZeneca's Prilosec OTC permits the companies to sell the proton pump inhibitor in packages containing more than one 14-day treatment regimen